An expanded access protocol of <scp>RT001</scp> in amyotrophic lateral sclerosis—Initial experience with a lipid peroxidation inhibitor

Abstract

RT001 was administered safely to a small group of people living with ALS in the context of an EA protocol. Currently, there is an ongoing randomized, double-blind, controlled study of RT001 in ALS.